Segue sotto una selezione degli articoli già pubblicati (non pre-print) su riviste scientifiche che rilevano in varie forme e modi, una serie di effetti collaterali già riscontrati.
(NB: siamo appena a 9 mesi dalla prima somministrazione – laddove un articolo scientifico ci mette 4-6 mesi o più solo per essere costruito, approvato e pubblicato).
• Pomara C., et al. Post-mortem findings in vaccine-induced thrombotic thombocytopenia https://haematologica.org/article/view/haematol.2021.279075
• Perry et al., “Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study”, in The Lancet
• Saif Abu Mouch, et al., Myocarditis following COVID-19 mRNA vaccination, in Vaccine (https://doi.org/10.1016/j.vaccine.2021.05.087);
• Supriya S. Jain et al., COVID-19 Vaccination-Associated Myocarditis in Adolescents, in Pediatrics, 2021 – doi: 10.1542/peds.2021-053427 https://pediatrics.aappublications.org/content/early/2021/08/12/peds.2021-053427
• George A. Diaz et al., Myocarditis and Pericarditis After Vaccination for COVID-19
• Montgomery et al., Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military, https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
• Bakir M, Almeshal et al., Toxic Epidermal Necrolysis Post COVID-19 Vaccination – First Reported Case, in Cureus 13(8): e17215. doi:10.7759/cureus.17215
• Darrell, O. Ricke, Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies, in Front. Immunol. 12:640093. doi: 10.3389/fimmu.2021.640093
• Nouara Yahi et al., Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?, in Journal of Infection
• Cheng et al., Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review
• Watad et al, Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination
• Talotta, R., Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases
• Correa e al., “Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence?” https://www.ijidonline.com/article/S1201-9712(20)32506-6/fulltext